GWN-323
- Generic Name
- GWN-323
Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas
- First Posted Date
- 2016-04-15
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 92
- Registration Number
- NCT02740270
- Locations
- 🇪🇸
Novartis Investigative Site, Barcelona, Catalunya, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath